Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
- Conditions
- Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
- Interventions
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 321
- Registration Number
- NCT00704483
- Locations
- 🇬🇧
Novartis, Salford, United Kingdom
🇺🇸Novarits, Fargo, North Dakota, United States
🇬🇧Novartis Investigative Site, Portsmouth, United Kingdom
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT00702052
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Hillman Cancer Center (4), Pittsburgh, Pennsylvania, United States
🇺🇸Bay Area Cancer Research Dept.ofBayAreaCancerResearch, Concord, California, United States
🇺🇸Georgia Health Sciences University Dept. of MCG, Augusta, Georgia, United States
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT00700271
- Locations
- 🇹🇳
Investigative sites in Tunisia, Tunisia, Tunisia
🇫🇷Investigative sites in France, Paris, France
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00698464
- Locations
- 🇩🇪
Novartis Investigative site, Berlin, Germany
🇿🇦Novartis Investigative Site, George, South Africa
🇧🇪Universite Catholique de Louvain, Brussels, Belgium
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
- Conditions
- Cutaneous T-Cell LymphomaLeukemia-Lymphoma, Adult T-Cell
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT00699296
- Locations
- 🇯🇵
Okayama University Hospital, Okayama, Japan
🇯🇵University Hospital of Occupational and Environmental Health, Fukuoka, Japan
🇯🇵Imamura Bun-in Hospital, Kagoshima, Japan
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 384
- Registration Number
- NCT00698646
- Locations
- 🇺🇸
Investigative Site, Taylors, South Carolina, United States
🇺🇸Investigative Sites, Pismo Beach, California, United States
🇺🇸Investigative site, St George, Utah, United States
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 965
- Registration Number
- NCT00699192
- Locations
- 🇮🇹
Investigative site Italy, Rome, Italy
🇨🇿Investigative sites Czech Republic, Praha, Czech Republic
🇸🇪Investigative site Sweden, Malmo, Sweden
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
- Conditions
- Symptomatic Refractory Resistant Carcinoid Disease
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT00690430
- Locations
- 🇺🇸
University of Arizona / Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale, Arizona, United States
🇺🇸Loma Linda University Dept. of Loma Linda CancerCent, Loma Linda, California, United States
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
- Conditions
- Advanced and Metastatic Silent Neuro-Endocrine TumorsNeuroendocrineNon Functioning Neuroendocrine Tumors (NETs)Non Syndromic Neuroendocrine TumorsCarcinomaCarcinoidsNon Functioning
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT00688623
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 261
- Registration Number
- NCT00688909
- Locations
- 🇺🇸
Tenessee Oncology, Nashville, Tennessee, United States
🇺🇸Cancer Care of Kansas, Wichita, Kansas, United States
🇺🇸Augusta Oncology, Augusta, Georgia, United States